Mundipharma
Anna joined Mundipharma in 2016 as Head of HR for the Mundipharma Nordic independent associated companies. She has through her career held senior global, European and regional HR roles with a focus on business transformation. Her broad cross-cultural experience is from across industries (Qlik, Yves Rocher, SAS Hotels), giving Anna a deep understanding for how to inspire and lead teams in multiple countries through a transformational journey, including the transformation of the Mundipharma Nordic independent associated companies.
Anna has BA degree in Public Administration, and did her Executive MBA at Instituto de Empresa in Madrid, Spain.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.